Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1
Tim Wilhelmi, Xingbo Xu, Xiao-Ying Tan, Melanie S. Hulshoff, Sabine Maamari, Samuel Sossalla, Michael Zeisberg, Elisabeth M. Zeisberg
Abstract
: This study is the first to identify that Serelaxin increases the expression of its own receptor RXFP1 and that this mediates the inhibition of EndMT and cardiac fibrosis, suggesting that Serelaxin may have a beneficial effect as anti-fibrotic therapy in chronic heart failure.
Topics & Concepts
RelaxinCardiac fibrosisMedicineHeart failureFibrosisAngiotensin IIMyocardial fibrosisEndothelial dysfunctionEndotheliumInternal medicinePharmacologyCardiologyReceptorPregnancy-related medical research